vs Gray Dwarf Hamster

Clitopilus passeckerianus compared with Cricetulus migratorius

Key Differences

• is Not Evaluated while Gray Dwarf Hamster is Least Concern.

Taxonomic Classification

Rank		Gray Dwarf Hamster
Kingdom	Fungi (Fungi)	Animalia (Animals)
Phylum	Basidiomycota (Club Fungi)	Chordata (Chordates)
Class	Agaricomycetes (Mushrooms)	Mammalia (Mammals)
Order	Agaricales (Gilled Mushrooms)	Rodentia (Rodents)
Family	Entolomataceae	Cricetidae
Genus	Clitopilus	Cricetulus
Species	Clitopilus passeckerianus	Cricetulus migratorius

Conservation Status

NE — Not Evaluated

Gray Dwarf Hamster

LC — Least Concern

Physical Characteristics

Attribute		Gray Dwarf Hamster
Diet	—	—
Average Lifespan	—	—
Average Length	—	—
Average Weight	—	—

Habitat & Geographic Range

Habitat

Typically found in forest floors, decomposing wood, and soil ecosystems.

Range

Distributed across Norway and Sweden.

Gray Dwarf Hamster

Habitat

Typically found in diverse terrestrial and aquatic ecosystems.

Clitopilus passeckerianus is a white-rot agaric fungus in the family Entolomataceae notable for its role as a natural producer of pleuromutilin, a diterpenoid antibiotic compound that serves as the biosynthetic precursor for the veterinary and human antibiotic drugs tiamulin and valnemulin, used to treat Mycoplasma infections in livestock. First described from European woodland habitats, the species produces the characteristic Clitopilus fruiting body: a pale, whitish cap with decurrent, crowded gills becoming pinkish at maturity from angular spores, and a farinaceous odor. Its antibiotic-producing capacity makes C. passeckerianus of significant pharmaceutical interest, and biosynthetic studies of pleuromutilin production have informed synthetic chemistry approaches to antibiotic development. The species inhabits temperate deciduous woodland floors in Europe, fruiting in autumn among leaf litter. Discovery of its pleuromutilin biosynthetic pathway has opened avenues for heterologous expression and semi-synthetic modification aimed at developing novel antibiotics to counter antibiotic-resistant bacterial pathogens.